Generation Bio (NASDAQ:GBIO) Reaches New 12-Month High at $43.73

Generation Bio Co. (NASDAQ:GBIO) shares hit a new 52-week high on Monday . The stock traded as high as $43.73 and last traded at $43.55, with a volume of 1015 shares traded. The stock had previously closed at $43.26.

GBIO has been the subject of a number of research analyst reports. ValuEngine upgraded Generation Bio from a “hold” rating to a “buy” rating in a research report on Monday, October 19th. BidaskClub upgraded Generation Bio from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Finally, Zacks Investment Research upgraded Generation Bio from a “sell” rating to a “hold” rating in a research report on Tuesday, October 13th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $32.33.

The company’s fifty day moving average price is $28.26.

Generation Bio (NASDAQ:GBIO) last announced its quarterly earnings results on Sunday, November 15th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.01). On average, sell-side analysts expect that Generation Bio Co. will post -2.9 EPS for the current year.

Several large investors have recently made changes to their positions in GBIO. Bank of New York Mellon Corp purchased a new position in Generation Bio during the second quarter valued at approximately $635,000. Ensign Peak Advisors Inc acquired a new position in Generation Bio during the second quarter valued at approximately $2,750,000. FMR LLC acquired a new position in Generation Bio during the second quarter valued at approximately $135,836,000. Victory Capital Management Inc. acquired a new position in Generation Bio during the second quarter valued at approximately $17,823,000. Finally, Gilder Gagnon Howe & Co. LLC acquired a new position in Generation Bio during the second quarter valued at approximately $1,486,000. 61.08% of the stock is owned by hedge funds and other institutional investors.

Generation Bio Company Profile (NASDAQ:GBIO)

Generation Bio Co, a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of eight programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.

See Also: Calculating net profit and net profit margin ratio

Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.